company background image
TE1 logo

Bio-Techne DB:TE1 Stock Report

Last Price

€57.00

Market Cap

€9.0b

7D

-3.4%

1Y

-14.3%

Updated

16 Mar, 2025

Data

Company Financials +

TE1 Stock Overview

Develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. More details

TE1 fundamental analysis
Snowflake Score
Valuation4/6
Future Growth4/6
Past Performance2/6
Financial Health6/6
Dividends0/6

Community vs My Fair Value

Create Narrative

Select a narrative for quick price alerts from the community, or create your own.

Bio-Techne Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for Bio-Techne
Historical stock prices
Current Share PriceUS$57.00
52 Week HighUS$78.50
52 Week LowUS$53.50
Beta1.29
1 Month Change-8.80%
3 Month Change-20.28%
1 Year Change-14.29%
3 Year Change-40.31%
5 Year Change42.50%
Change since IPO398.03%

Recent News & Updates

Recent updates

Shareholder Returns

TE1DE Life SciencesDE Market
7D-3.4%-1.6%-0.5%
1Y-14.3%-15.8%15.5%

Return vs Industry: TE1 exceeded the German Life Sciences industry which returned -15.8% over the past year.

Return vs Market: TE1 underperformed the German Market which returned 15.5% over the past year.

Price Volatility

Is TE1's price volatile compared to industry and market?
TE1 volatility
TE1 Average Weekly Movement5.1%
Life Sciences Industry Average Movement7.0%
Market Average Movement5.3%
10% most volatile stocks in DE Market12.0%
10% least volatile stocks in DE Market2.8%

Stable Share Price: TE1 has not had significant price volatility in the past 3 months compared to the German market.

Volatility Over Time: TE1's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19763,100Kim Keldermanwww.bio-techne.com

Bio-Techne Corporation, together with its subsidiaries, develops, manufactures, and sells life science reagents, instruments, and services for the research, diagnostics, and bioprocessing markets worldwide. The company operates through two segments, Protein Sciences, and Diagnostics and Genomics. The Protein Sciences segment develops and manufactures biological reagents used in various aspects of life science research, diagnostics, and cell and gene therapy, such as cytokines and growth factors, antibodies, small molecules, tissue culture sera, and cell selection technologies.

Bio-Techne Corporation Fundamentals Summary

How do Bio-Techne's earnings and revenue compare to its market cap?
TE1 fundamental statistics
Market cap€9.03b
Earnings (TTM)€145.28m
Revenue (TTM)€1.10b

62.2x

P/E Ratio

8.2x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
TE1 income statement (TTM)
RevenueUS$1.20b
Cost of RevenueUS$404.01m
Gross ProfitUS$792.00m
Other ExpensesUS$633.90m
EarningsUS$158.10m

Last Reported Earnings

Dec 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)1.00
Gross Margin66.22%
Net Profit Margin13.22%
Debt/Equity Ratio14.4%

How did TE1 perform over the long term?

See historical performance and comparison

Dividends

0.5%

Current Dividend Yield

32%

Payout Ratio

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/03/16 20:24
End of Day Share Price 2025/03/14 00:00
Earnings2024/12/31
Annual Earnings2024/06/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bio-Techne Corporation is covered by 27 analysts. 13 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
James Francis MainwaringAtlantic Equities LLP
Catherine Ramsey SchulteBaird